Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP

YUJIN KOBAYASHI1, YOSHIHIRO HATTA1, ATSUKO HOJO1, YOSHIMASA KURA3, YOSHIHITO UCHINO1, HIROMICHI TAKAHASHI1, SATOMI KISO1, YUKIO HIRABAYASHI1, MAI YAGI1, HITOMI KODAIRA1, DAISUKE KURITA1, TOSHIKAKE TANAKA1, KATSUHIRO MIURA1, NORIYOSHI IRIYAMA1, SUMIKO KOBAYASHI1, UMHIKO SAWADA3, MASAKIYO SUGITANI2 and JIN TAKEUCHI1

Departments of 1Hematology and Rheumatology, and 2Pathology, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo 173-8610; 3Department of Hematology and Oncology, Kasukabe Municipal Hospital, 7-2-1 Chuo Kasukabe, Saitama 344-8588, Japan

Received September 16, 2011; Accepted November 10, 2011

DOI: 10.3892/etm.2011.387

Abstract. The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP (i.e., R-CHOP)] is considered to be the standard regimen for treating localized, primary gastric diffuse large B-cell lymphoma (PG-DLBCL). However, few studies have reported the long-term efficacy of R-CHOP therapy in the management of localized PG-DLBCL. In the present study, we performed a retrospective analysis of 11 patients with localized PG-DLBCL, who were treated with R-CHOP at Nihon University Itabashi Hospital and Kasukabe Municipal Hospital (Japan) from 2001 to 2008. Limited stage cancer was defined as stage I/II according to the Lugano staging system for gastrointestinal (GI) lymphomas. The relative dose intensity (RDI) of CHOP therapy was calculated for each patient. The median age of the patients was 68 years (range, 48-82). Gastralgia and anemia were common symptoms at initial presentation. All patients except 1 received 6 cycles of R-CHOP treatment without consolidative radiation therapy or prior surgery. RDI was maintained at over 80% in 9 out of 11 patients. All patients achieved complete remission and the estimated overall survival with a median follow-up of 54 months (range, 39-103) was 100%, without relapse or significant GI adverse effects, such as perforation or bleeding during R-CHOP treatment. No long-term adverse effects of rituximab were recorded during the observation period. Helicobacter pylori infection was diagnosed in 72.7% (8 cases) of the patients, but was eradicated in a limited number of patients. Our data suggest the feasibility and effectiveness of the addition of rituximab to conventional CHOP therapy in the management of localized PG-DLBCL.

Introduction

Primary non-Hodgkin's lymphoma of the gastrointestinal (GI) tract represents 3-4% of all malignancies arising in the digestive tract. The most commonly involved site is the stomach (60% of cases) (1). Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has been treated with various modalities, including surgery, chemotherapy and radiotherapy alone or in combination with other methods. Chemotherapy using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens is considered to be the treatment of choice, due to its preferable outcomes (2-5). On the contrary, surgery, which until a few decades ago was deemed an essential first-line therapeutic intervention, is now relegated to patients with massive bleeding or perforation at presentation. Several studies have demonstrated that the extent of surgery has no impact on the outcome of GI lymphoma (6); it is now believed that non-surgical treatments achieve equal or better results than gastrectomy (7).

Rituximab, an anti-CD20 monoclonal antibody, has emerged as an effective therapy for numerous CD20-positive hematological malignancies (8). Highly promising results have been obtained in combination with chemotherapy, and the results of a randomized study comparing rituximab in addition to CHOP (R-CHOP) with CHOP alone in nodal DLBCL patients have shown superior response and survival rates for the R-CHOP regimen (9). Although the impact of the addition of rituximab to chemotherapy regimens has not been tested by conducting large clinical trials in patients with PG-DLBCL (10), its addition is considered preferable owing to proven therapeutic benefits in nodal DLBCL patients (11-12).

Taking these data into account, R-CHOP has been used increasingly as the primary treatment for patients with localized PG-DLBCL. To the best of our knowledge, only few studies reporting the long-term efficacy of the R-CHOP regimen in
this cohort have been published, with a median follow-up of 15 months (range, 4–42) (10). We performed a retrospective analysis of patients diagnosed with localized PG-DLBCL and treated with the R-CHOP regimen in the Nihon University Itabashi Hospital and Kasukabe Municipal Hospital (Japan), with a longer median follow-up of 54 months (range, 39–103). This study investigated the feasibility and effectiveness of the addition of rituximab to conventional CHOP therapy in the management of localized PG-DLBCL.

Patients and methods

Patients with localized PG-DLBCL undergoing treatment with R-CHOP, from January 2001 to December 2008, at the Nihon University Itabashi Hospital and Kasukabe Municipal Hospital were analyzed. All patients diagnosed with PG-DLBCL underwent esophagogastroduodenoscopy, and biopsy samples were obtained. Whole-body computed tomography (CT) scanning and bone marrow aspiration were included as lymphoma staging procedures. Positron emission tomography or gallium scanning were also used for staging. Colonoscopy was not routinely performed. The stage at presentation was assessed according to the Lugano staging system, and the localized stage was defined as stage I/II (13). Histologically, DLBCL was defined according to the criteria outlined in the WHO classification (14). A proton pump inhibitor (PPI) or histamine H2 receptor antagonist was used for treatment. The urea breath test (15), enzyme-linked immunosorbent assay (serological test to detect IgG antibodies) (16–17), biopsy urease test (18) or histological examinations were used to investigate the presence of *Helicobacter pylori* (*H. pylori*) infection.

The standard R-CHOP regimen (day 1: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² and days 1–5: prednisone 40 mg/m²) was aimed to be administered at 21-day intervals. All patients were subjected to 6 curative cycles, and each cycle was repeated every 3 weeks. Following completion of treatment, re-evaluation of the treatment response by gastroscopy with biopsy and CT of the thorax and abdomen was performed. All patients diagnosed with PG-DLBCL, treated with R-CHOP at our institution responded to treatment, with a longer median follow-up of 54 months (range, 39–103) following treatment, no patients succumbed to the disease or experienced relapse. Patient number 1 experienced gastric adenocarcinoma while in continuous CR 8 months following chemotherapy and was subsequently treated with a successful endoscopic mucosal resection. Patient number 3 experienced a cerebral infarction unrelated to lymphoma while in continuous CR, 51 months following the start of chemotherapy. No patients received additional radiation therapy. Patient number 2 received a reduced dose of CHOP therapy due to old age, organ dysfunction and poor performance status during initial treatment.

Acute toxicity associated with R-CHOP therapy, which was mainly hematological in nature, was mostly tolerated by patients. A total of 9/11 (81.8%) patients developed granulocytopenia of grade 3–4 during treatment and 4/11 (36.4%) patients developed febrile neutropenia or infection with grade 3–4 neutropenia. Patient number 6 developed recurrent septicaemia (*Escherichia coli* or candidemia) during the first and second cycle of CHOP treatment, respectively, necessitating the cancellation of subsequent CHOP therapy. RDI was maintained at over 80% in the majority of patients, except patients number 2 and 6 due to comorbidities and infection. No GI bleeding or gastric perforations were noted. Reactions to rituximab were only mild with standard premedication. No signs of late rituximab toxicity such as viral infections or late-onset neutropenia were observed.

Results

Our study identified 11 patients (7 females and 4 males) aged 48–82 years (median 68), who were administered R-CHOP for the treatment of localized PG-DLBCL (Table I). No patients were HIV-positive. All patients were chemosensitive and none had undergone prior surgery. All patients, except patient number 6, were subjected to 6 cycles of R-CHOP therapy. A total of 8 patients displayed evidence of *H. pylori* infection at diagnosis. At initial presentation, 7/11 (63.6%) patients had gastralgia (abdominal pain) and 5/11 (45.4%) had anemia (defined as hemoglobin levels below 14 g/dl in males and 12 g/dl in females), but no patients had hematemesis or melena. Weight loss, defined as the B-symptom, was found in 4/11 (36.4%) patients (21). All 11 patients (100%) achieved a complete response (CR). During the observation period with a median follow-up of 54 months (range, 39–103) following treatment, no patients succumbed to the disease or experienced relapse.

Relative dose intensity (RDI). In order to estimate the dose of antitumor agents, the RDI of CHOP was calculated as previously described by Epsteinbaum et al (20). Firstly, the planned full dose of the drug per cycle (mg/m²) was divided by the scheduled number of weeks in the cycle (week). Secondly, in order to determine the actual DI for each drug, the total dose of drug actually received by the patient (mg/m²) was divided by the total number of weeks actually required to receive the total dose (week). Thirdly, the actual DI of each drug was divided by the standard DI of the same drug. Fourthly, the average RDI of CHOP was calculated as the sum of RDI of cyclophosphamide, doxorubicin, vincristine and prednisone and divided by 4. In total, in the present study, 6 cycles of standard CHOP regimen administered on 21-day intervals was regarded as full RDI (100%). Rituximab was not included in the calculation.

Discussion

Treatment for PG-DLBCL has shifted from surgery to gastric preservation methods, including chemotherapy and/or radiotherapy, in order to aid organ conservation. Certain retrospective and prospective studies have suggested that gastrectomy is unnecessary (4.22–24) except during serious complications such as perforation, obstruction and hemorrhaging during non-surgical treatments. However, these analyses were performed prior to the introduction of rituximab. All patients treated with R-CHOP at our institution responded to treatment, and had continuous CR, which suggests that PG-DLBCL, similar to nodal DLBCL, is a highly chemosensitive and potentially curable disease. No adverse effects such as bleeding or perforation were observed in the patients included in this study, who were all administered concomitant therapy with oral PPIs or histamine H2 receptor antagonist on a routine basis.
It is believed that the initial treatment of DLBCL should be maintained to the same dosage schedule for older individuals as for younger adults (25). We previously reported that older patients with DLBCL may be treated with standard R-CHOP, the same as younger patients if their comorbid condition is tolerable (26). Recently, the entity of the RDI was proposed as an index of the intensity of chemotherapy. Hirakawa et al. previously reported that RDI maintenance in the chemotherapy of DLBCL improved the treatment results even in the rituximab era (27). They showed that an actual RDI of less than 70% was an independent prognostic factor for a low overall and progression-free survival. A high RDI maintained among the majority of patients in this study was considered to be one of the possible causes of favorable long-term outcome.

A prospective, randomized study carried out by Bonnet et al., which compared CHOP alone with CHOP plus radiotherapy, involved field radiation in almost 600 patients older than 60 years of age, with aggressive lymphoma of stages I and II (28). However, only a small number of gastric lymphomas were examined in this study. There was no advantage of combined treatment over chemotherapy alone regarding 5-year event-free and overall survival. As in other types of DLBCL, the standard regimen of primary gastric DLBCL in its early stages is currently rituximab in combination with CHOP (9). Patients with more limited gastric lesions (diameter of less than 5 cm) have previously been treated with radiotherapy alone (29); however, at present these patients are also treated with combined modality treatment (i.e. chemotherapy and radiotherapy) (30). The precise role of radiotherapy in gastric DLBCL is still an issue of debate as most data in the literature come from retrospective studies. It is possible that additional radiation may be restricted to patients with low grade mucosa associated lymphoid tissue (MALT) components not responding to H. pylori eradication therapy, as well as patients with DLBCL and a bulky tumor (31).

Among the 11 patients, 8 (72.7%) were positive for H. pylori infection (1 negative and 2 not checked). In Japan, more than 70-80% of adults born before 1950, and 45% of those born after 1950 are infected with H. pylori (32). Moreover, the number of siblings is also linked to a higher acquisition of H. pylori infection (33,34). In the present study, 10 out of the 11 patients were born prior to 1950, and the average number of siblings of all patients was 3.7 (data not shown). H. pylori eradication was not routinely performed at our institution due to histological evidence of DLBCL and the priority that R-CHOP therapy be initiated immediately upon diagnosis. In contrast to gastric MALT lymphoma, the role of H. pylori infection in PG-DLBCL is controversial. As reported previously, H. pylori eradication resulted in durable histologically confirmed CR in 50-63% of patients with gastric DLBCL and concomitant MALT (35). The eradication of H. pylori may be necessary in PG-DLBCL, particularly in cases of concomitant MALT lymphoma (36).

The most common documented adverse event associated with rituximab is an acute infusion reaction (37). However, with the increase in the number of patients treated with rituximab, long-term hematological or infectious adverse events occurring following the administration of rituximab have been reported more frequently (8). A recently published systematic review evaluating infectious complications of monoclonal

<table>
<thead>
<tr>
<th>#</th>
<th>Patient no.</th>
<th>Gender</th>
<th>Age (years)</th>
<th>IPI</th>
<th>Lugano stage</th>
<th>Follow-up (months)</th>
<th>RDI (%)</th>
<th>H. pylori infection</th>
<th>ECOC PS</th>
<th>Response</th>
<th>CR</th>
<th>R-CHOP</th>
<th>Relapse</th>
<th>Event-free survival</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>M</td>
<td>62</td>
<td>II2</td>
<td>Low</td>
<td>103</td>
<td>90.9</td>
<td>+</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>90.9</td>
<td>Alive</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>M</td>
<td>82</td>
<td>II2</td>
<td>Low</td>
<td>80</td>
<td>61.3</td>
<td>+</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>61.3</td>
<td>Alive</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>F</td>
<td>71</td>
<td>II2</td>
<td>Low</td>
<td>55</td>
<td>80.3</td>
<td>+</td>
<td>B</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>80.3</td>
<td>Alive</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>F</td>
<td>48</td>
<td>I</td>
<td>Low</td>
<td>6</td>
<td>89.6</td>
<td>+</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>89.6</td>
<td>Alive</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>M</td>
<td>67</td>
<td>II2</td>
<td>Low</td>
<td>1</td>
<td>13.9</td>
<td>-</td>
<td>B</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>13.9</td>
<td>Alive</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>M</td>
<td>81</td>
<td>II1</td>
<td>Low</td>
<td>NC</td>
<td>2</td>
<td>+</td>
<td>B</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>2</td>
<td>Alive</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>M</td>
<td>70</td>
<td>I</td>
<td>Low</td>
<td>1</td>
<td>96.4</td>
<td>+</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>96.4</td>
<td>Alive</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>M</td>
<td>59</td>
<td>I</td>
<td>Low</td>
<td>1</td>
<td>90.2</td>
<td>-</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>90.2</td>
<td>Alive</td>
</tr>
<tr>
<td>9</td>
<td>9</td>
<td>F</td>
<td>60</td>
<td>I</td>
<td>Low</td>
<td>6</td>
<td>96.9</td>
<td>+</td>
<td>B</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>96.9</td>
<td>Alive</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>M</td>
<td>68</td>
<td>I</td>
<td>Low</td>
<td>1</td>
<td>93.7</td>
<td>+</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>93.7</td>
<td>Alive</td>
</tr>
<tr>
<td>11</td>
<td>11</td>
<td>M</td>
<td>68</td>
<td>I</td>
<td>Low</td>
<td>1</td>
<td>91.2</td>
<td>-</td>
<td>A</td>
<td>CR</td>
<td></td>
<td>CR</td>
<td>No</td>
<td>91.2</td>
<td>Alive</td>
</tr>
</tbody>
</table>

**Table I.** Clinical outcome of PG-DLBCL patients treated with R-CHOP.

**Gender:** M, male; F, female; IPI, International Prognostic Index; ECOG PS, Eastern Cooperative Oncology Group performance status; H. pylori, Helicobacter pylori; NC, not checked; RDI, relative dose intensity; CR, complete remission; PG-DLBCL, primary gastric diffuse large B-cell lymphoma; R-CHOP, rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone.

**Table Legend:**
- CR: complete remission
- R-CHOP: rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone
antibodies administered in cancer patients failed to demonstrate a significant increase in the incidence of infections with the addition of rituximab to chemotherapy (38). Despite some controversies, we believe that close monitoring of patients receiving rituximab enables us to use rituximab safely.

Avilés et al recently reported the results of a phase II clinical trial to assess the efficacy and toxicity of the addition of rituximab to chemotherapy in cases of primary gastric lymphoma (PGL). They concluded that the addition of rituximab to CHOP chemotherapy did not improve the outcome in cases of low clinical risk, early-stage PGL with a favorable outcome of 5-year overall survival of 95%, compared with historical controls treated with CHOP monotherapy (39). Some limitations of this study included the small number of patients participating in the study and that conclusions were based upon the comparison with historical controls (4). A recent report by Leopardo et al detailed a retrospective study of stage I-IV gastric DLBCL. Patients treated with rituximab plus chemotherapy alone (40). They concluded that rituximab plus chemotherapy yielded a statistically significant advantage in terms of continuous CR (100 vs. 76.6%, P=0.004) at 5 years. A poor outcome with chemotherapy alone may have resulted from the fact that advanced diseases, which were graded stage III-IV in the Lugano staging system, were included in this study.

Two innovative methods to observe the entire small intestine were recently introduced: wireless capsule endoscopy (WCE) and double-balloon enteroscopy (DBE) (41). The two modalities enable high-resolution visualization of the entire small intestine in order to detect lymphoma. Since WCE or DBE were not routinely available during the present study, the exact frequency of lymphoma involvement in the small intestine is unknown. In contrast to follicular lymphoma in the GI tract, the frequency of small intestine involvement in gastric DLBCL is not precisely known. Further investigation with WCE or DBE will be useful for accurately evaluating disease distribution in the case of GI-tract lymphoma.

Although the outcome of adding rituximab to CHOP therapy should be evaluated by a large-scale randomized trial, difficulties collecting prospective data associated with this rare malignancy may prevent such an undertaking. In clinical practice, rituximab is usually combined with CHOP-like regimens as in the case of nodal DLBCL therapy (42). Our results demonstrate the feasibility and effectiveness of the addition of rituximab to conventional CHOP therapy in the management of localized PG-DLBCL, and suggest that R-CHOP be considered as a standard clinical trial in patients with localized PG-DLBCL.

Acknowledgements

We would like to thank to Ms. Mako Sonobe and Shiori Hirasawa for administrative support.

References


